Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PENICILLAMINE vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Wilson's disease,Cystinuria,Rheumatoid arthritis,Lead poisoning,Mercury poisoning,Arsenic poisoning
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic metabolism to S-methyl-penicillamine and penicillamine disulfide; also undergoes renal excretion.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
~80% bound to plasma proteins, primarily albumin.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Vd: 0.1–0.2 L/kg; indicates distribution mainly in extracellular fluid and limited tissue penetration, though accumulates in skin and connective tissue.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 40–70% (variable due to food and metal ions).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl >=50 m L/min: no adjustment; Cr Cl 30-49 m L/min: reduce dose by 50%; Cr Cl 10-29 m L/min: reduce dose by 75%; Cr Cl <10 m L/min: avoid use.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No specific adjustments recommended; use with caution in severe hepatic impairment.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
For Wilson disease: 250 mg/m²/day orally in divided doses; for cystinuria: 30 mg/kg/day in divided doses; for rheumatoid arthritis: 2.5-5 mg/kg/day, titrated slowly.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at low end of dosing range; monitor renal function closely; increased risk of hematologic and autoimmune adverse effects.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None explicitly issued by FDA.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Bone marrow suppression (leukopenia, thrombocytopenia, aplastic anemia), proteinuria/nephrotic syndrome, autoimmune reactions (myasthenia gravis, Goodpasture's syndrome, lupus-like syndrome), severe skin reactions (toxic epidermal necrolysis), hepatotoxicity, cross-allergenicity with penicillin. Requires monitoring of CBC, urinalysis, liver function.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
History of aplastic anemia or agranulocytosis, severe renal insufficiency, pregnancy (especially first trimester), breastfeeding, hypersensitivity to penicillamine or penicillin.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid high-protein meals and dairy products around dosing; they decrease penicillamine absorption. Separate intake from iron supplements, antacids, and zinc by at least 2 hours. For cystinuria, maintain high fluid intake and possibly restrict sodium and methionine-rich foods (e.g., meats, dairy) as part of therapy.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or cystinuria. Second/third trimesters: Risk of fetal connective tissue defects; avoid unless essential.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Excreted in breast milk; M/P ratio approximately 0.1. Low concentrations are present; however, due to potential adverse effects (e.g., rash, bone marrow suppression), caution is advised. Consider monitoring infant for rash or blood dyscrasias.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustment is recommended based on pharmacokinetic changes alone; however, due to potential teratogenicity, use only when necessary. Therapeutic drug monitoring may be considered to ensure efficacy without excessive toxicity.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Penicillamine is a chelating agent used for Wilson disease, cystinuria, and rheumatoid arthritis. Monitor for bone marrow suppression, proteinuria, and autoimmune reactions. Administer on an empty stomach (1 hour before or 2 hours after meals). Avoid concurrent use with gold, antimalarials, or immunosuppressants due to increased toxicity. Discontinue if rash, fever, or lymphadenopathy develop.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take penicillamine on an empty stomach, at least 1 hour before or 2 hours after meals.,Avoid taking with milk, antacids, or iron supplements as they reduce absorption.,Report any unexplained bruising, bleeding, sore throat, or fever immediately.,Watch for signs of proteinuria (foamy urine) or hematuria (blood in urine).,Do not stop abruptly; dose tapering is required.,Use effective contraception; penicillamine can cause fetal harm.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Almasilate, an aluminum-containing antacid, can adsorb penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This leads to decreased serum concentrations of penicillamine, potentially diminishing its therapeutic effect in diseases such as rheumatoid arthritis or Wilson's disease. Clinically, this interaction may result in loss of disease control or require dose adjustments."
"Calcium carbonate, a common antacid and calcium supplement, chelates with penicillamine in the gastrointestinal tract, forming an insoluble complex that reduces penicillamine absorption. This interaction significantly decreases the bioavailability and serum concentration of penicillamine, potentially compromising its therapeutic efficacy in treating conditions such as rheumatoid arthritis or Wilson's disease. Clinical outcomes may include loss of disease control or increased disease activity, particularly if the drugs are taken concomitantly."
"Concomitant administration of penicillamine and teriflunomide may significantly increase the serum concentration of teriflunomide, primarily due to penicillamine's inhibition of the organic anion transporter 3 (OAT3)-mediated renal elimination of teriflunomide. Elevated teriflunomide levels heighten the risk of dose-dependent adverse effects, including hepatotoxicity, peripheral neuropathy, and immunosuppression. This interaction warrants careful monitoring and potential dose adjustment to avoid toxicity."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PENICILLAMINE vs ABSTRAL, answered by our medical review team.
PENICILLAMINE is a Chelating Agent that works by Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PENICILLAMINE and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PENICILLAMINE is: 250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PENICILLAMINE and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PENICILLAMINE is classified as Category C. First trimester: Known teratogen; associated with cutis laxa, congenital hip dislocation, and other skeletal abnormalities. Contraindicated unless treatment for Wilson disease or c. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.